in the fisa vaccine efficacy against breakthrough infections. that s distracting and there are some unintended harm of giving of does to people who are young and healthy. we have seen that with young boys at a high rate of one and 6,000, and there is no global equity issue. so it is distracting and is interfering with the global equity issue and i think it s not a good time to be talking about boosters for young healthy people. john: one of the things that you have talked about frequently is the spacing of vaccine doses. you have an editorial in mid page today where you say there is a growing body of research suggests robust immune response with extended dosing interval. so they have it at three weeks right now, you re suggesting and had been suggesting that it should be spaced out longer, but is anybody listening? i don t think so. unfortunately we are hearing guidance that is very top-heavy and assaying sticks to the three year four week interval after your first test of an mrna